Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
暂无分享,去创建一个
John T Brooks | Daniel Abebe | Charles E Rose | J. Brooks | C. Malotte | C. Hendrix | D. Smith | C. Rose | T. Sukalac | F. Soud | C. Hart | E. Buliva | Craig W Hendrix | L. Paxton | Jeffrey A Johnson | C Kevin Malotte | Dawn K Smith | Dawn K. Smith | Michael C Thigpen | Poloko M Kebaabetswe | Lynn A Paxton | Tebogo M Segolodi | Faith L Henderson | Sonal R Pathak | Fatma A Soud | Kata L Chillag | Rodreck Mutanhaurwa | Lovemore Ian Chirwa | Michael Kasonde | Evans Buliva | Roman J Gvetadze | Sandra Johnson | Thom Sukalac | Vasavi T Thomas | Clyde Hart | Faith L. Henderson | M. Kasonde | Tebogo M. Segolodi | M. Thigpen | S. Pathak | K. Chillag | P. Kebaabetswe | Sandra Johnson | R. Gvetadze | Vasavi Thomas | Daniel Abebe | Lovemore Chirwa | Rodreck Mutanhaurwa | D. Smith | Dawn K. Smith | Dawn K. Smith | Vasavi T. Thomas | Jeffrey A. Johnson | Dawn K. Smith | Evans Buliva
[1] C. Kenyon,et al. Antiretroviral preexposure prophylaxis for HIV prevention. , 2013, The New England journal of medicine.
[2] James D. Campbell,et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.
[3] Katrien Fransen,et al. Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.
[4] J. Stockman,et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men , 2012 .
[5] L. Grohskopf,et al. Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco , 2011, PloS one.
[6] P. Sax,et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. , 2011, The Journal of infectious diseases.
[7] W. Heneine,et al. Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. , 2011, The Journal of infectious diseases.
[8] Douglas J. Taylor,et al. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women: Supporting Online Material , 2010 .
[9] S. Buchbinder,et al. The HVTN Protocol 903 Vaccine Preparedness Study: Lessons Learned in Preparation for HIV Vaccine Efficacy Trials , 2008, Journal of acquired immune deficiency syndromes.
[10] D. Serwadda,et al. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward , 2008, The Lancet.
[11] Michael Monsour,et al. Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir , 2008, PLoS medicine.
[12] A. Haase,et al. Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice , 2008, PLoS medicine.
[13] Doug Taylor,et al. Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial , 2007, PLoS clinical trials.